AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new agreement to develop drugs for ...

Roche's chief medical officer, Levi Garraway. Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new ...

Domenico wrote that drug pricing is remarkable for its "puzzling opacity," but added that it is "not necessary to unravel the ...

For the first time, children in the US as young as two with the blood disorders sickle cell disease and beta thalassaemia are ...

The agency, consultancy, and investor segments saw a wave of senior-level appointments across April and May, as organisations ...

Novartis has secured EU approval for Itvisma, a new intrathecal formulation of its spinal muscular atrophy (SMA) gene therapy ...

This causes frustration for all stakeholders – sponsors, CROs, and eCOA providers alike. Yet, many of these challenges are ...

Orca Bio has become a commercial-stage company with the FDA approval of Tregzi, a cell-based immunotherapy designed to ...

As the US relaxes an export ban on Anthropic's advanced AI tools, the company formally launched Claude Science, an AI ...

Earlier this year, Daiichi Sankyo Global Head of Oncology Ken Keller told pharmaphorum about the company’s big year, with ...

Sanofi is preparing to expand the use of its Pompe therapy Nexviazyme, currently approved only for late-onset cases of the ...

Point-of-care (POC) healthcare marketing is on the rise, experiencing 171% revenue growth since 2019 to surpass $803 million ...